Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to Equity (FCFE)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Item | Description | The company |
---|---|---|
FCFE | Free cash flow to equity is the cash flow available to Merck & Co. Inc. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. | Merck & Co. Inc. FCFE increased from 2021 to 2022 and from 2022 to 2023. |
Price to FCFE Ratio, Current
No. shares of common stock outstanding | |
Selected Financial Data (US$) | |
Free cash flow to equity (FCFE) (in millions) | |
FCFE per share | |
Current share price (P) | |
Valuation Ratio | |
P/FCFE | |
Benchmarks | |
P/FCFE, Competitors1 | |
AbbVie Inc. | |
Amgen Inc. | |
Bristol-Myers Squibb Co. | |
Danaher Corp. | |
Eli Lilly & Co. | |
Gilead Sciences Inc. | |
Johnson & Johnson | |
Moderna Inc. | |
Pfizer Inc. | |
Regeneron Pharmaceuticals Inc. | |
Thermo Fisher Scientific Inc. | |
P/FCFE, Sector | |
Pharmaceuticals, Biotechnology & Life Sciences | |
P/FCFE, Industry | |
Health Care |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | ||||||
Selected Financial Data (US$) | ||||||
Free cash flow to equity (FCFE) (in millions)2 | ||||||
FCFE per share3 | ||||||
Share price1, 4 | ||||||
Valuation Ratio | ||||||
P/FCFE5 | ||||||
Benchmarks | ||||||
P/FCFE, Competitors6 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Moderna Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
P/FCFE, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
P/FCFE, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
3 2023 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
4 Closing price as at the filing date of Merck & Co. Inc. Annual Report.
5 2023 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =
6 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/FCFE | Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. | Merck & Co. Inc. P/FCFE ratio increased from 2021 to 2022 and from 2022 to 2023. |